RGEN vs. UTHR: Repligen vs. United Therapeutics Stock Comparison

November 11, 2026

How do Repligen (RGEN) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Repligen (RGEN) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RGEN is classified in Life Sciences Tools & Services while UTHR is classified in Biotechnology.

Company profile comparison for Repligen (RGEN) and United Therapeutics (UTHR)
Profile Item	RGEN	UTHR
Name	Repligen Corporation	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	11.09 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	April 29, 1986	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

RGEN

UTHR

GSPC

Repligen (RGEN) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Repligen (RGEN) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Repligen (RGEN) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
Total Return (1Y)	23.28%	28.77%
Total Return (3Y, Annualized)	6.20%	37.63%
Total Return (5Y, Annualized)	-8.41%	23.78%

Risk Profile

Drawdown History

RGEN

UTHR

GSPC

Repligen (RGEN) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Repligen (RGEN) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
Volatility (1Y, Annualized)	46.73%	35.00%
Beta (5Y)	1.11	0.49
Max Drawdown (5Y)	-64.67%	-33.00%
Avg. Volume (3M)	1.18M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

RGEN and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
Sharpe Ratio (1Y)	0.41	0.70
Sortino Ratio (1Y)	0.60	1.29

Profitability

ROE (TTM)

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max: 109.18%
Q3: 6.23%
RGEN: -0.57%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile United Therapeutics (UTHR) reports 38.61%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
RGEN: -1.47%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

United Therapeutics (UTHR) at 28.99% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max: 83.12%
Q3: 14.77%
RGEN: 6.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
ROE (TTM)	-0.57%	19.13%
ROA (TTM)	1.40%	10.91%
Net Margin (TTM)	-1.47%	38.61%
Operating Margin (TTM)	6.19%	28.99%
Gross Margin (TTM)	53.77%	86.34%

Growth

Revenue Growth

Both Repligen (RGEN) at 16.36% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
Revenue Growth (YoY)	16.36%	10.61%
Revenue Growth (3Y CAGR)	-2.70%	18.02%
EPS Growth (YoY)	--	13.07%
EPS Growth (3Y CAGR)	-35.73%	22.92%

Financial Strength

Current Ratio (MRQ)

Both Repligen (RGEN) at 9.88 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max: 25.13
Q3: 12.13
RGEN: 9.88
Median: 5.52
Q1: 2.47
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Repligen (RGEN) carries debt-to-equity ratio of 0.33 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max: 1.42
Q3: 0.65
RGEN: 0.33
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Repligen (RGEN) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; RGEN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
Current Ratio (MRQ)	9.88	4.61
Debt / Equity (MRQ)	0.33	--
Net Debt / EBITDA	-1.19	-1.53

Dividends

Dividend Yield (TTM)

Neither Repligen (RGEN) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Repligen (RGEN) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RGEN: --

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Repligen (RGEN) vs. United Therapeutics (UTHR): RGEN does not report P/E ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Repligen (RGEN) at 13.77 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max: 58.18
Q3: 25.77
RGEN: 13.77
Median: 7.30
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Repligen (RGEN) at 4.70 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max: 13.53
Q3: 6.54
RGEN: 4.70
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Repligen (RGEN) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Repligen (RGEN) and United Therapeutics (UTHR)
Metric	RGEN	UTHR
P/E Ratio (TTM)	--	21.22
P/S Ratio (TTM)	13.77	7.51
P/B Ratio (MRQ)	4.70	3.80
Free Cash Flow Yield (TTM)	1.01%	1.90%